US Stock MarketDetailed Quotes

LXEO Lexeo Therapeutics

Watchlist
  • 13.960
  • -0.010-0.07%
Close May 15 16:00 ET
459.92MMarket Cap-6622P/E (TTM)

About Lexeo Therapeutics Company

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Company Profile

SymbolLXEO
Company NameLexeo Therapeutics
Listing DateNov 3, 2023
Issue Price11.00
Founded2017
CEOMr. Richard Nolan Townsend
MarketNASDAQ
Employees58
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address345 Park Avenue South,6th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10010
Phone1-212-547-9879
Websitehttp://www.lexeotx.com

Company Executives

  • Name
  • Position
  • Salary
  • Richard Nolan Townsend
  • Director and Chief Executive Officer
  • 1.74M
  • Jenny R. Robertson, J.D.
  • Chief Business and Legal Officer
  • 1.30M
  • Dr. Sandi See Tai, M.D.
  • Chief Development Officer
  • --
  • Dr. Eric Adler, M.D.
  • Chief Medical Officer and Head of Research
  • 3.04M
  • Dr. Steven Altschuler, M.D.
  • Chairman of the Board
  • 200.15K
  • Mette Kirstine Agger
  • Independent Director
  • 10.50K
  • Paula H.J. Cholmondeley
  • Independent Director
  • 406.61K
  • Reinaldo M. Diaz
  • Independent Director
  • 7.38K
  • Dr. Brenda Cooperstone, M.D.
  • Independent Director
  • 529.14K
  • Bernard Davitian
  • Independent Director
  • 6.41K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg